Credit Suisse Group reiterated their neutral rating on shares of AstraZeneca plc (LON:AZN) in a research note released on Monday, MarketBeat reports. Credit Suisse Group currently has a GBX 5,000 ($63.70) price target on the biopharmaceutical company’s stock.

A number of other brokerages also recently issued reports on AZN. Barclays PLC reaffirmed an overweight rating and set a GBX 6,000 ($76.44) price target on shares of AstraZeneca plc in a report on Monday, June 5th. J P Morgan Chase & Co reaffirmed a neutral rating on shares of AstraZeneca plc in a report on Monday, June 5th. Deutsche Bank AG reaffirmed a buy rating and set a GBX 5,700 ($72.62) price target on shares of AstraZeneca plc in a report on Monday, June 5th. Liberum Capital reissued a buy rating and issued a GBX 5,500 ($70.07) target price on shares of AstraZeneca plc in a report on Monday, June 5th. Finally, Kepler Capital Markets reissued a buy rating and issued a GBX 5,500 ($70.07) target price on shares of AstraZeneca plc in a report on Monday, June 5th. Four investment analysts have rated the stock with a sell rating, eight have given a hold rating and nine have assigned a buy rating to the company’s stock. The stock has a consensus rating of Hold and an average price target of GBX 5,171.80 ($65.89).

Analyst Recommendations for AstraZeneca plc (LON:AZN)

AstraZeneca plc (LON AZN) traded up 1.48% during midday trading on Monday, reaching GBX 5423.00. The company’s stock had a trading volume of 642,574 shares. AstraZeneca plc has a 1-year low of GBX 3,680.00 and a 1-year high of GBX 5,505.00. The firm’s market capitalization is GBX 68.66 billion. The stock’s 50-day moving average price is GBX 5,118.49 and its 200 day moving average price is GBX 4,699.54.

WARNING: “AstraZeneca plc’s (AZN) Neutral Rating Reaffirmed at Credit Suisse Group” was reported by Daily Political and is the sole property of of Daily Political. If you are accessing this article on another website, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The original version of this article can be viewed at https://www.dailypolitical.com/2017/06/20/astrazeneca-plcs-azn-neutral-rating-reaffirmed-at-credit-suisse-group.html.

About AstraZeneca plc

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.